Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

AASLD 2026
This is the logo of the provider
AASLD 2026 5 - 9 November 2026

Effects of zalfermin, cagrilintide, and semaglutide on non-invasive fibrosis biomarkers in alcohol-related liver disease: ​A phase 2 randomized trial

Authors :

Vijay Shah1; Juan Pablo Arab2; Ramon Bataller3; Jerome Boursier4; Jacob George5; Lise Lotte Gluud6; Kenichi Ikejima7; Maria Rodrigo-Domingo8; Mazen Noureddin9,10; ​Jörn M. Schattenberg11,12; Ahsan Shoeb8,13; Irina Yoffe8; Aleksander Krag14
Affiliations
View Details Hide Details
This is the logo of the provider
{{ getPageNum(PDFPage) }}
Download the poster (.pdf)
Keywords
MASH
Congress oral presentation
GLP-1 RA
Semaglutide
PHASE 2 (RCT)